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ABSTRACT
 Colorectal cancer (CRC) presents in one of three patterns: sporadic colorectal cancer in those without a 
family history (65-85%); those with a family history (familial CRC)  10-25% of cases; inherited CRC accounting 
for less of 10% cases and presents as well-characterized cancer predisposition syndromes including Lynch 
syndrome (hereditary non-polyposis colorectal cancer/HNPCC) which comprises about 1-5% of all colorectal 
cancer, and multiple polyps CRC, which includes familial adenomatous polyposis (FAP,1%), rare CRC syndrome 
< 0.1 %). 
Many efforts have been made to discover the genetic and molecular features of CRC, and there is more 
evidence that these features determine the prognosis and response to treatment. Colorectal cancer (CRC) is 
a heterogeneous disease, with three known major molecular groups. The most common is the chromosomal 
LQVWDELOLW\JURXSFKDUDFWHUL]HGE\DQDFFXPXODWLRQRIPXWDWLRQVLQVSHFL¿FRQFRJHQVDQGWXPRUVXSSUHVVRU
genes. The second is the microsatellite instability group, caused by the dysfunction of DNA mismatch repair 
genes leading to genetic hypermutability. The CpG island methylation phenotype (CIMP) is the third group, 
distinguished by hypermethylation. In this review we would like to provide an up-to-date overview of molecular 
genetic aspects of CRC that are currently important and should guide clinical practice in colorectal cancer in 
the diagnosis and selection of therapy. 
Keywords: sporadic colorectal cancer, molecular diagnostics, chromosomal instability (CIN), microsatellite 
instability (MSI), CpG island methylation phenotype (CIMP) 
ABSTRAK 
Kanker kolorektal (KKR) muncul dalam bentuk satu dari tiga pola yang ada: kanker kolorektal sporadik 
pada mereka yang tidak memiliki riwayat keluarga (65-85%); mereka yang memiliki riwayat keluarga yang 
menderita kanker kolorektal 10-25% kasus; dan KKR inherited (inherited CRC) yang jumlahnya kurang dari 
10% kasus, dikelompokkan sebagai sindrom predisposisi kanker, yaitu Lynch syndrome (herediter non-poliposis 
kanker kolorektal) yang terjadi sekitar 1-5% dari semua kanker kolorektal, dan kanker kolorektal polip multipel, 
yang mencakup familial adenomatosa poliposis (FAP, 1%), sindrom kanker kolorektal langka < 0,1%.
Banyak upaya telah dilakukan untuk menemukan bentuk genetik dan molekuler kanker kolorektal, dan ada 
lebih banyak bukti bahwa bentuk ini menentukan prognosis dan respon terhadap pengobatan. Kanker kolorektal 
adalah penyakit heterogen dengan tiga kelompok utama molekuler yang diketahui. Yang paling sering ditemukan 
DGDODKNHORPSRNLQVWDELOLWDVNURPRVRPGLWDQGDLGHQJDQDNXPXODVLPXWDVLSDGDRQNRJHQ\DQJVSHVL¿NGDQ
gen supresor tumor. Yang kedua adalah kelompok instabilitas mikrosatelit, yang disebabkan oleh disfungsi gen 
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perbaikan kesalahan DNA yang mengarah pada hipermutabilitas genetik. CpG island methylation phenotype 
(CIMP) adalah kelompok ketiga, ditandai dengan hipermetilasi. Dalam ulasan ini, akan diberikan gambaran 
terkini tentang aspek genetik molekuler dari CRC yang dianggap penting dan diharapkan dapat dijadikan 
pedoman pada praktik klinis kanker kolorektal dalam diagnosis dan pemilihan terapi. 
Kata kunci: kanker kolorektal sporadik, diagnostik molekuler, instabilitas kromosom, instabilitas mikrosatelit, 
CpG island methylation phenotype (CIMP)
INTRODUCTION
Colorectal cancer (CRC) is the 3rd most frequent 
cancer in Western Countries, and the 2nd leading 
cause of cancer death in the United States. CRC is 
therefore considered a major health problem.1 CRC is 
caused by the loss of genomic stability that drives the 
development of CRC by facilitating the acquirement of 
tumor-associated mutations. Several forms of genomic 
LQVWDELOLW\KDYHEHHQLGHQWL¿HGLQFOXGLQJFKURPRVRPDO
instability (CIN), microsatellite instability (MSI), and 
epigenetic gene silencing.2
The molecular biological markers status of CRC 
patients are now considered the important factors 
to determine either the possibility of successful 
treatment for CRC (predictive factor) or life expectancy 
(prognostic factor). Clinical applications of genomic 
medicine and molecular diagnostics based on testing of 
tumor tissues are becoming a reality in clinical practice, 
ZLWKVLJQL¿FDQWLPSDFWRQSHUVRQDOL]HGWKHUDSLHVIRU
cancer patients. Advances in targeted therapies for 
CRC have recently emerged and are rapidly moving 
targets.32XU¿QGLQJV VXJJHVW WKDW FDQFHU ORFDWLRQV
(proximal, distal colon and rectum) differ in their 
associated molecular alterations in carcinogenesis.4,5
EPIDEMIOLOGY OF COLORECTAL CANCER
Colorectal cancer (CRC) is the third most commonly 
diagnosed cancer, with over 1.2 million new cases each 
year, and the second leading cause of cancer-related 
mortality, with approximately 600,000 deaths each 
year.1 In Europe, some 447,000 new cases of CRC, and 
215,000 deaths occurred in 2012. Incidence rates vary 
by ~20-fold. Highest incidences are in North America, 
Western Europe, Australia, New Zealand, and Japan, 
lowest in India and Northern Africa. 
The population in Indonesia is more than 
235,000,000 and the age standarized incidence rates 
per 100,000 for CRC by gender was 19.1 for male 
and 15.6 for female, and CRC displayed a tendency 
to occur in patients under the age of 40 with the 
proportion of 35.26%. The study of 760 patients who 
have been examined by colonoscopy at Pirngadi 
Hospital Medan revealed 197 (25.9%) of the patient 
had colorectal cancer, 16.8% of them were under 40 
years old and most of CRC were located in the rectum 
(74.6%) than in colon (18.8% distal and 6.6% proximal 
colon).6,7,8,9 CRC incidence rates are rapidly increasing 
due to the effect of many risk factors. The underlying 
causes of CRC are complex and heterogenous. Both 
environmental factors and genetic events contribute 
to CRC risk. 
PATHOGENESIS OF COLORECTAL CANCER
Inherited and familial CRC derive, at least in part, 
from germline mutations.  Familial CRC presents 
without precisely defined Mendelian inheritance 
patterns or genetic etiology. Sporadic CRC derives from 
somatic mutations, and is not associated with family 
history.10 CRC is a heterogeneous complex of diseases. 
0ROHFXODUIHDWXUHLVLPSRUWDQWEHFDXVHLWUHÀHFWVWKH
mechanisms of carcinogenesis. In molecular aspects, 
CRC develops via accumulation of genetic mutations. 
Progression to CRC is considered a step wise process, 
with an accumulation of various genetic and epigenetic 
alterations, leading to transformation from a normal 
FHOOWRDSUHPDOLJQDQWWXPRUDQG¿QDOO\WRDPDOLJQDQW
and potentially metastatic tumor.11,12 Growing evidence 
suggests that epigenetic changes might even be higher 
than the genetic changes and are major determinant 
in the origin of the tumor and tumor heterogeneity.10 
Risk Factors for CRC are divided into: (a) non-
PRGL¿DEOHULVNIDFWRUV: age more than 40-50; personal 
or family history of CRC or adenomatous polyps; 
LQÀDPPDWRU\ERZHOGLVHDVH,%'XOFHUDWLYHFROLWLV
and Crohn’s Disease, increase risk 8-10 years after 
initial diagnosis; familial syndrome (FAP, HNPCC, 
MUTYH associated polyposis, Peutz-Jeghers, Juvenile 
SRO\SRVLV EPRGL¿DEOH ULVN IDFWRUV GLHW KLJK LQ
unsaturated fat and red meat or processed meat, high-
IDWORZ¿EHUGLHWSK\VLFDOLQDFWLYLW\REHVLW\DOFRKRO
environment, use of cigarettes and other tobacco 
products.1
,Q RUGHU WR ¿QG QHZGLDJQRVWLF DQG WKHUDSHXWLF
solutions that could help reduce CRC related deaths, 
it is important to understand the etiological biological 
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nature of CRC. Understanding the molecular genesis 
RI&5&LVDIXQGDPHQWDOVWHSLQWKHLGHQWL¿FDWLRQRI
PROHFXODUWDUJHWVWKDWPLJKWEHXVHIXOLQGH¿QLQJWKH
prognosis of CRC patients and their therapy.11,12, 13,14,15
CLINICAL MANIFESTATION
Early colon cancer usually has no symptoms. 
Signs and symptoms typically occur only in advanced 
colon cancer. Approximately, 25% of CRC present 
with metastases at initial diagnosis. Patient complain 
of changes in bowel habits lasting more than a few 
days: diarrhea, constipation, or a feeling that the 
bowel does not empty completely, feeling or being 
bloated. Bleeding from the rectum, blood in the stool, 
cramping or gnawing stomach, cramps, weakness and 
fatigue, unexplained weight loss, constant tiredness, 
or unexplained anemia (iron deficiency). Clinical 
presentation related CRC locations, in proximal 
colon cancers: iron deficiency anemia, melena, 
hematochezia, obstruction (rare), fatigue, weakness. 
Distal colon cancer: hematochezia, abdominal pain, 
REVWUXFWLRQRYHUÀRZGLDUUKHDFKDQJHVLQERZHOKDELW
left quadrant discomfort and weight loss, may develop. 
Bleeding from the rectum in rectal cancer.6,7
Colorectal tumors spread to other parts of the 
body by direct extension into adjacent structures and 
metastasis through the lymphatics and blood vessels. 
The favoured metastatic sites of colorectal cancer are 
lymph nodes, liver, lung and bones. Metastatic diseases 
(50% of CRC patients will develop metastases): 
right upper quadrant (RUQ) pain, ascites, weight 
loss, fatigue. Other symptoms: symptoms from 
local invasion (bladder, small bowel); may mimic 
diverticulitis; fever of unknown origin.14
GENERAL DIAGNOSTIC EVALUATION
General diagnostic evaluation are colonoscopy, 
chest x-ray, abdominal ultrasound or computerized 
tomography (CT) of chest abdomen and pelvis. 
Laboratory test for hepatic function panel, 
carcinoembryonic antigen (CEA). Kirsten rat sarcoma 
(KRAS) mutation status in patients with metastatic 
disease. MSI testing or IHC examination for MMR 
protein expressions for patients under 50 years old. 
Diagnostic evaluation for localized staging of rectal 
cancer: Transrectal ultrasound (TRUS): 80-95% 
accuracy of distinction between T1/2 vs. T3 tumors. 
Magnetic resonance imaging (MRI) is high degree of 
accuracy for prediction of circumferential resection 
margin, less operator dependent, allows for study of 
stenotic tumors and pelvic adenopathy. TRUS and 
MRI may provide complementary information. CT 
scan helpful for staging distant metastases, limited for 
local tumor and nodal staging.14
7DEOH6WDJLQJSURJQRVLVDQGWUHDWPHQWRIFRORUHFWDOFDQFHU14
Stage T N M \6XUYLYDO(%) Tx
I T1-2 N0 93 Surgery alone
IIA T3 N0 85 Surgery± adjuvant 
chemo*
IIB T4 N0 72 Surgery± adjuvant 
chemo*
IIIA T1-2 N1 83 Surgery± adjuvant 
chemo (5-FU/Cap + 
OX (MOSAIC NEJM 
2004;350:2343
IIIB T3-4 N1 64
IIIC T1-4 N2 44
IV M1 5 Chemoterapy ± 
surgeryb
 DEVROXWHEHQH¿WIURPDGMXYDQW)848$6$5/DQFHW
	PD\EHQH¿WSWVZSUHVHQFHRISRRUULVNIHDWXUHVO\PSKRYDVFXODULQYDVLRQ
or LVI, perineural invasion  or PNI, poorly differentiated histology, +LN, 
perforation, clinical obstruction, inadequate LN sampling [<12])
b 3WVZOLPLWHGKHSDWLFRUSXOPPHWVPD\EHQH¿WIURPPHWDVWDVHFWRP\HLWKHU
preceded or followed by chemotherapy
7DEOH6WDJLQJDQGWUHDWPHQWRIUHFWDOFDQFHU14
Stage T N M Tx
I cT1 cN0 Surgery alone (local excision)
I cT2 cN0 Surgery alone (total mesorectal 
excision or TME)
II A cT3 cN0 Neoadj chemoradiation 
w/5-FU or Cap followed 
by resection, followed by 
adjuvant chemotherapy (NEJM 
2004;351:1731)
II B cT4 cN0
III A CT1-2 cN1
III B CT3-4 cN1
III C cT1-4 cN2
IV M1 Chemotherapy ± surgeryb
*  T1-2 N0 should be based on assessment by TRUS or MRI. If pathologic 
staging indicates > T2 disease, positive LN, or high risk features, adjuvant 
chemotherapy & chemoradiotherapy are recommended in either order. High 
risk features include (+) margins, LVI, PNI, poorly differentiated tumors, or 
deep submucosal invasion
b 3WVZOLPLWHGKHSDWLFRUSXOPPHWVPD\EHQH¿WIURPPHWDVWDVHFWRP\HLWKHU
preceded or followed by chemotherapy
0ROHFXODU 7HVWLQJ RI &RORUHFWDO &DQFHUV IRU
Targetted and conventional Therapy
Molecular testing of CRC from tumor tissues has 
important implications for the treatment selection in 
CRC patients. Fresh tissue obtained from colorectal 
tumors, either by colonoscopic biopsy or surgery. 
Tumor tissues immediately fixated by using 10% 
IRUPDOGHK\GHEXIIHULQJVROXWLRQDQGPDGHLQWRSDUDI¿Q
blocks or formalin- fixed and paraffin-embedded 
tissues (FFPET). It is used for the examination of : 
histology of the tumor, immunohistochemical test for 
the evaluation of the protein expression of mismatch 
repair (MMR) or MSI status and CIN; while those 
tumor tissue is also used for examining microsatellite 
instability by polymerase chain reaction (PCR).5,16 
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The treatment approaches by using the molecular 
test results of CRC tumor tissue will give information 
for the selection of individualized therapy, representing 
the principles of personalized tumor diagnostics and 
targeted therapy. The application of tissue molecular 
testing of CRC discussed here considers the CIN, 
deoxyribonucleic acid (DNA) mismatch repair status 
and MSI, and CIMP, and takes into consideration the 
mutational status of the EGFR signaling pathway to 
select targeted therapy. 
Chromosomal Instability
Chromosomal Instability (CIN) is characterized by 
any chromosomal copy number or structure change. 
CIN is the commonest genomic instability that 
encompasses 80-85% of all CRC and adenoma. It is 
suggested that CIN induces carcinoma through the 
loss or mutation of tumor suppressor genes such as 
APC, TP 53, and also through activation of oncogenes 
such as KRAS. CRC caused by CIN usually have poor 
prognosis.17,18,19
In the RAS family, KRAS gene plays the most 
important role. The activation of RAS genes can 
promote cell survival and suppress apoptosis. Most 
KRAS mutations occur in codon 12 (70-80%) and 
codon 13 of exon 2. In clinical applications, KRAS 
mutation analysis is widely used as a prognostic and 
predictive biomarker for anti_EGFR monoclonal 
antibodies like cetuximab and panitumumab to 
predict the therapeutic effectiveness in CRC. KRAS 
mutations predicts lack of response to therapy with 
antibodies targeted to EGFR. No role of anti EGFR in 
KRAS mutant colorectal cancers. Apart from KRAS, 
recent clinical studies start to focus on v-raf murine 
sarcoma viral oncogene homologue B1 (BRAF) and 
neuroblastoma-ras (NRAS). Mutations in BRAF occur 
in approximately 12% of all CRCs patients and it is 
mutually exclusive of KRAS mutation. Investigation 
of BRAF mutations is also recommended when KRAS 
mutation are not found. NRAS is closely related to 
KRAS, and found in approximately in 3-5% of all CRC 
patients. It occurs in codon 61. NRAS mutations are 
mutually exclusive of KRAS mutations. 
Adenomatous polyposis coli (APC) gene plays a 
crucial role in the Wnt/Wingless pathway. APC gene 
is the most important gatekeeper of colonic epithelial 
cell proliferation and it is responsible for controlling 
WKHXQGHUO\LQJRQFRSURWHLQFDOOHGȕFDWHQLQ7KHORVV
of function in APC gene may lead to the transition 
to adenoma from normal colonic mucosa due to the 
XSUHJXODWLRQRI ȕFDWHQLQ6RPDWLF$3&PXWDWLRQV
are present in most sporadic colorectal adenomas and 
cancers. Similar to KRAS, APC mutations appear in 
the early stage of the progression from adenoma to 
carcinoma.18,19
7DEOH0ROHFXODUELRORJ\WHVWLQFRORUHFWDOFDQFHUPRGL¿HG
Name/ method
Target ,QWHQGHGXVH
Detected 
property
6RXUFH
material
0ROHFXODU
Method
Use/
availability
KRAS TD EGFR 
TT
KRAS
Mutation
FFPET or SFT Sequencing Clinical 
routine
KRAS TD EGFR 
TT
KRAS
Mutation
FFPET or SFT SnaPshot/Strip assay, COLD PCR, ARMS, 
PNA clamping, 
Digital PCR
Studies.
BRAF Chemoth.
Suscept.
BRAF mutations FFPET or SFT Sequencing, Real time PCR. Clinical 
routine
BRAF Chemoth.
Suscept.
BRAF mutations FFPET or SFT. Digital PCR, COLD –PCR Studies.
06,VWDWXV
PCR
Chemoth.
Suscept.
 MSI status FFPET or SFT PCR Clinical 
routine
06,VWDWXV
IHC
Chemoth.
Suscept.
MSI status FFPET IHC Clinical 
routine
005VWDWXV Chemoth.
Suscept.
(CTS)
MMR/ MSI FFPET IHC, PEN of MLH1, MSH2,PMS2 and MSH6. Clinical/ 
studies
APC PEN Chemoth.
Suscept.
CIN FFPET IHC Studies
06,VWDWXVPL51$ Chemoth.
Suscept.
MSI status FFPET or SFT Oligonucleotide microarray Studies
73PXWDWLRQ Screening P53 mutation 
analysis
 FFPET or SFT Sequencing Clinical 
routine
73PXWDWLRQ Screening P53 mutation 
analysis
FFPET or SFT Oligonucleotide microarray Studies
CIMP Probable 
screening/
staging
Methylation FFPET or SFT  Methylation microarray Studies
miRNA assay for 
blood/stool
Screening miRNA 
expression level
Plasma/
Stool
Microarray Studies
$3&$GHQRPDWRXVSRO\SRVLVFROL3(1SURWHLQH[SUHVVLRQQHJDWLYH))3(7)RUPDOLQ¿[HGSDUDI¿QHPEHGGHGWLVVXHV6)76QDSIUR]HQWLVVXH&76&KHPR
therapeutic susceptibility; TD EGFR TT: Therapeutic decision EGFR targeted therapy
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'HR[\ULERQXFOHLF DFLG '1$0LVPDWFK5HSDLU
Defects and Microsatellite Instability
Microsatellite are short tandem repeats of 
nucleotides that occur throughout the genome. In 
FHOOVZLWKGH¿FLHQWPLVPDWFK UHSDLU HUURUV LQ'1$
replication accumulate and are detectable in these 
UHJLRQVLGHQWL¿HGDVPLFURVDWHOOLWHLQVWDELOLW\06,
Approximately 15% of all CRCs show underlying 
defects in DNA mismatch repair (dMMR) and the 
tumor tissues show microsatellite instability (MSI). In 
3-5% of MSI-positive (MSI-high) CRC, patients harbor 
germline mutations related to the Lynch syndrome and 
the remaining 12% or so are sporadic CRC.3 
MSI-positive status (MSI-H) correlated with 
the tumors being in the proximal colon and with 
improved survival.3 This was soon followed by the 
identification of genes responsible for hereditary 
non-polyposis colorectal cancer (HNPCC) MSH2 and 
MLH1. Subsequently, MSI has been shown to play 
a role in sporadic CRC.3 At least six different genes 
(MSH2, MLH1,PMS1, hPMS2, MSH6 and MLH3) 
encode the mismatch repair system. Assessment of 
MSI status can be done by immunohistochemistry to 
evaluate expression of DNA mismatch repair protein 
that show protein expression negative (PEN), or by 
PCR-based DNA testing for MSI to assess instability 
at microsatellite sequences.5,16, 20 CRC patients with 
06,+ VWDWXV UHFHLYLQJÀXRURXUDFLO )8 VKRZHG
no improvement in disease-free survival, and infact, 
treatment was associated with reduced overall survival 
21. Regimens with 5-FU alone should be avoided 
in these patients with stage II CRC who may be 
candidates for chemotherapy. 
Microsatellite Instability
Microsatellite instability (MSI) accounts for 15% 
of CRC. It is characterized by an altered length of 
the gene with small deletions and insertions of short 
repetitive deoxyribonucleic acid (DNA) sequences 
(microsatellite) distributed throughout the genome. 
Single MSI within the whole genome may have no 
VLJQL¿FDQWHIIHFWVEXWDFFXPXODWLRQRIWKHPXWDWLRQV
can result in frame shifts within gene coding sequences 
and the subsequent inactivation of the genes would give 
rise to the progression of the tumor. The underlying 
cause of MSI can be explained by two mechanism: 1) 
defective mismatch repair (MMR) system, in which 
both allells of a MMR gene (MLH1, MSH2, MSH6, 
and PMS2) are non-functional. This results in the loss 
of ability to repair DNA replication mismatches in 
the affected cells; 2) hypermethylation of promoter in 
MMR genes that suppress the expression of the genes 
like MLH1.17,18,22
Polymerase chain reaction (PCR) based methods 
and immunohistochemistry (IHC) can be used to detect 
MSI-H. IHC staining detects DNA MMR system protein 
such as MLH1 and MSH2. The loss in these markers 
is indicative of MSI. In our study differences in the 
characteristics of chromosome instability (CIN), MMR 
and MSI CRC found in the proximal, distal colon and 
rectum were desribed. The tissues with adenocarcinoma 
were examined by IHC and PCR. IHC was done 
to examine the APC protein expression negative 
(APC-PEN), MMR-PEN (MLH1,MSH2,MSH6 and 
PMS2). MSI by PCR based on 5 markers of BAT25, 
BAT26, D2S123, D5S346,D17S250, which were 
SHUIRUPHG06,+ZDVFRQVLGHUHG LI WKHUHZHUH
of abnormal markers.4,5 IHC staining is best performed 
ZKHQ WKH WXPRU WLVVXH VSHFLPHQVDUH¿[HGSURPSWO\
and properly since the quality of staining would be 
affected. Furthermore, the size of the specimens is also 
DFRQFHUQLQVWDLQLQJ7KH06,FODVVL¿FDWLRQV\VWHPLV
highly valuable in prognosis and therapy since standard 
FKHPRWKHUDS\XVLQJÀXRURXUDFLO LVQRW HIIHFWLYH LQ
treating MSI-high tumors. Instead, irinotecan-containing 
regimens have shown improved responses and better 
prognosis for MSI-High tumors.19,22
Epigenetic Gene Silencing
It is mostly caused by DNA methylation. Cancers 
with high degree of methylation can be considered 
as CpG island phenotype (CIMP) positive, and 
CIMP encompasses 35-40% of sporadic CRC. DNA 
methylation is involved in normal cellular control of 
gene expression. The methylation patterns of these 
CpG sequences are gene-specific. Aberrant CpG 
hypermethylation can lead to silencing of tumor-
suppressor genes in carcinogenesis since the expression 
of the genes is repressed. For example, p16, p14, 
MGMT, and hMLH1 are commonly silenced genes in 
CRC patients. In some cases, the presence of epigenetic 
silencing overlapps with MSI. Some sporadic CRC 
with microsatellite instability is caused by DNA 
methylation. For example, DNA methylation of MLH1 
gene promoter blocks its expression and destroys the 
ability of MMR system.17,18,23,14 CpG regions that are 
hypermethylated in CRC when compared to normal 
individuals are valuable for biomarkers development. 
The methylation of MLH1 associated silencing is 
widely used as prognostic and predictive markers for 
CRC.15,17,24 
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7DUJHWLQJ (SLGHUPDO *URZWK )DFWRU 5HFHSWRU
(*)56LJQDOOLQJ3DWKZD\VLQ&RORUHFWDO&DQFHU
Aberrant activation of EGFR signaling pathways is 
frequent in CRC, and is primarily activating mutations 
of genes in these pathways MAPK and PI3K. The 
following are the proportions of cases harboring various 
mutations in EGFR pathways genes: MAPKinase 
pathway: KRAS (40-45%), NRAS (2.5%), BRAF 
(5-10%); PI3Kinase pathway: PIK3CA (15%), PTEN 
(10-20%), AKT (5%); combined mutations: KRAS/
NRAS and PI3K (10%). 
$QLQWHUHVWLQJ¿QGLQJLV WKDW LQ&5&DV LQRWKHU
tumors, RAS and RAF mutations are mutually 
exclusive. Therefore, together, BRAF and KRAS are 
mutated in about half of all CRC cases.3,25,26,27 KRAS 
mutations are found in about 40-45% of all colorectal 
cancers and occur mostly at exon 2 [codon 12 (70-
80%) or 13 (20-30%)], while there are rare mutations 
in codons 61 and 146. BRAF mutations occur most 
commonly at exon 15 with thymine to adenine 
transversion at nucleotide position 1796, which leads to 
the substitution of valine for glutamate (a substitution 
mutation termed V600E), and are found in about 5-10% 
of all colorectal cancers. Importantly the BRAF V600E 
PXWDWLRQRFFXUV LQRI'1$005SUR¿FLHQW
tumors (microsatellite stable; MSS) and in 40-74% 
RI06,+VSRUDGLF&5&0/+GH¿FLHQWEXWLVQRW
IRXQG LQ0/+GH¿FLHQW06,+&5& LQ+13&&
associated CRC. Mutations in the PI3K axis are seen 
in about 20% of all CRC cases. 
The role of EGFR pathway gene mutations in the 
clinical management of CRC has been extensively 
studied. In terms of prognosis, KRAS mutations do 
not confer a poor prognosis, however, BRAF mutations 
FRQIHUDVLJQL¿FDQWO\SRRUHUSURJQRVLVDVDFRPSDUHG
to wild-type BRAF tumors. More importantly, the 
EGFR pathway has become an important therapeutic 
target. Cetuximab and panitumumab are anti EGFR 
antibodies that target the extracellular domain of 
the receptor. They have been shown to improve 
progression-free, and in some cases, overall survival 
in metastatic colorectal cancer. A landmark paper 
by Karapetis et al published in 2008 showed that in 
patients with wild-type KRAS tumors, treatment with 
cetuximab as compared with supportive care alone 
VLJQL¿FDQWO\LPSURYHGRYHUDOOVXUYLYDOPHGLDQ
vs. 4.8 months). In contrast, in patients with mutated 
.5$6 WXPRUV WKHUHZDV QR VLJQL¿FDQW GLIIHUHQFH
between those who were treated with cetuximab and 
those who were not. Several study concluded that 
patients with a colorectal tumor bearing mutated KRAS 
GLGQRWEHQH¿WIURPFHWX[LPDEZKHUHDVSDWLHQWVZLWK
ZLOGW\SH.5$6&5&GLG EHQH¿W IURP FHWX[LPDE
therapy. 
Patients with metastatic CRC who are candidates 
for anti EGFR antibody therapy should have their 
tumor tested for KRAS mutations. There is up to 
40% response rate to anti EGFR therapy in wild-type 
CRC while the remainder 60% wild-type tumors will 
not respond, presumably due to other gene/protein 
alterations in the EGFR or other signaling pathways. 
The predictive role of BRAF mutational studies in 
CRC is still unclear. While BRAF activating mutations 
should act similar to KRAS in terms of predicting and 
prognosticating. 28,29,30,31
)XWXUH0ROHFXODU'LDJQRVWLFVLQ&RORUHFWDO&DQFHU
DQG&RORUHFWDO$GHQRPDPL51$'HWHFWLRQ
MicroRNAs (miRNAs) are small non-coding RNA 
that are usually 19-23 nucleotids in length. Due to 
their small sizes, miRNAs are more stable in blood 
and FFPE tissues than other nucleic acids such as 
DNA and RNA. MicroRNAs (miRNAs) are involved 
in post-transcriptional regulation of gene expression. 
Therefore, they are able to function as oncogenes or 
tumor suppressor genes, and dysregulation of miRNA 
would be associated to cancers. Recent studies showed 
that miRNAs circulate in a stable and cell free form in 
WKHEORRGVWUHDP7KHUHIRUHPL51$VWKDWDUHVSHFL¿F
WR&5& LQEORRG VDPSOHVPD\EH LGHQWL¿HG IRU WKH
development of non-invasive prognostic and predictive 
markers of the disease.
miR-135a and miR-135b play important roles in 
the regulation of the Wnt/Wingles pathway by down-
regulating APC gene expression. miR-17-3p and miR-
92a have been found to be elevated in plasma and their 
levels decreased after removal of the cancer tissues. In 
the plasma of CRC patients, circulating miR-92 and 
miR-17 concentrations have been reported to be elevated 
in the preoperative samples and the concentrations were 
markedly reduced in the postoperative samples. Those 
results suggested that circulating miR-92 and miR-17 
are potential non-invasive diagnostic markers for CRC. 
Apart from the miRNAs mentioned above, miR-211 is 
also believed to be a potential marker for the diagnosis 
and prognosis of CRC.2,11,20
CONCLUSION
This review aims to summarize the issues on the 
use of biomarkers for determination of prognosis and 
monitoring of response to therapy. KRAS mutational 
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analysis of CRC tumor tissues is recommended as the 
standard of care in patients who are candidates for 
targeted anti-EGFR antibody therapy. Some experts 
now recommend whole RAS sequencing. In large 
practice centers, the trend is to test all colorectal 
adenocarcinomas for KRAS codon 12-13 mutations, 
for BRAF V600E mutations, and for microsatellite 
instability, thus allowing for selection of patients for 
conventional therapy as well as targeted therapy. In the 
last decade, the median survival of CRC patients has 
LQFUHDVHGVLJQL¿FDQWO\aZLWKWKHLQWURGXFWLRQ
of new routine diagnostics and personalized therapies. 
 It is obvious that determination of molecular 
predictive factors analyzed in routine diagnostics 
before selection of chemotherapy is important for 
individualized treatment in colorectal cancer. The 
optimal treatment strategy for metastatic CRC should 
be discuss in team work. The availability of multiple 
therapies and the judicious use of surgery have 
improved outcomes for metastatic CRC. Several 
biomarkers associated with predictive and prognostic 
values are available.
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